The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index; 53 of the 249 sources its claims cite were checked for support.
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
Open accessAbstract
Context: Insulin resistance is common in women with polycystic ovary syndrome (PCOS). Inositol may have insulin sensitizing effects; however, its efficacy in the management of PCOS remains indeterminate. Objective: To inform the 2023 international evidence-based guidelines in PCOS, this systematic review and meta-analysis evaluated the efficacy of inositol, alone or in combination with other therapies, in the management of PCOS. Data Sources: Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 2022. Study Selection: Thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses were included. Data Extraction: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. Data Synthesis: Thirteen comparisons were assessed, with 3 in meta-analyses. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes, and the evidence is very uncertain for body mass indexI. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited. Conclusion: The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found limited and inconclusive evidence that inositol improves PCOS outcomes, with some low-certainty metabolic/hormonal benefits for DCI or MI plus folic acid. Metformin was superior to MI for waist-hip ratio and hirsutism, while MI caused fewer gastrointestinal adverse events.
Key findings
- Across 30 RCTs (n = 2230; 1093 intervention, 1137 control), 19 studies contributed to meta-analyses; most outcomes were low to very low certainty.
- DCI vs placebo showed low-certainty benefits for free testosterone (MD −0.46), SHBG (MD 1.79), DHEAS (MD −139.43), AUC insulin (MD −3.65), AUC glucose (MD −20.85), triglycerides (MD −31.95), and ovulation (OR 11.50), but placebo was superior for BMI (MD 0.67).
- MI + FA vs FA showed very-low-certainty improvements in fasting insulin (MD −4.17) and HOMA-IR (MD −1.24), with no differences in BMI, clinical pregnancy rate, positive hCG, or ovulation rate.
- MI vs metformin: metformin was superior for FG score (MD 2.42) and WHR (MD 0.04); MI was superior for SHBG (MD 3.85) and GI adverse events (OR 0.09), with no differences in reproductive outcomes.
Methods
- Systematic review and meta-analysis following PRISMA, prospectively registered with PROSPERO (CRD 42022356057), to inform the 2023 International Evidence-based PCOS Guideline.
- Searched Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 5, 2022; included RCTs of females with PCOS diagnosed by Rotterdam, NIH, or AEPCOS criteria, comparing inositol alone or combined with other therapies.
- Data extracted by one reviewer and verified by a second; risk of bias assessed with Cochrane Risk of Bias 1.0, certainty with GRADE, and trial integrity with the RIGID framework; random-effects meta-analyses used where possible.
Limitations
- The paper states it included only English-language studies, did not search grey literature, found generally high risk of bias, and had small sample sizes/study numbers that precluded some meta-analyses and lowered certainty.
- The paper states adverse events were not reported by the majority of studies (23/29), and only one study examined adolescents, limiting comparisons in that subgroup.
- The text also makes evident that planned subgroup analyses for menopausal stage, adolescents/adults, and BMI category were not conducted due to the small number of trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
34 Valid · 5 Not valid · 66 Not checked · 90 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“However, metformin was superior to MI for the outcome of WHR in analysis of 2 trials (MD 0.04, Fig. 5M) (26, 41, 42).”
- Also stated in: § Meta-analyses · plain
“| 2 | RCT | Serious risk of biass | No serious inconsistency | No serious indirectness | Serious imprecisiont | None | 80 | 80 | MD 0.04[0.01,0.06] | Met | ⨁⨁◯◯LOW | IMPORTANT |”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Meta-analyses
What the sources say
- Supportedcites [26] Angik, 2015, A comparative study of metabolic and hormonal effects of myoinositol vs metformin in women with polycystic ovary syndrome: a randomised controlled trial, Int J Reprod Contracept Obstet Gynecol source
Our copy is one of the randomised myo-inositol vs metformin trials in PCOS that such a pooled WHR analysis would pool, and its Table 3 (RESULTS) gives exactly the metformin-favouring WHR contrast: myoinositol 0.79 ± 0.10 → 0.80 ± 0.07 (P = 0.088, NS) versus metformin 0.79 ± 0.08 → 0.76 ± 0.06, with an I vs. M between-group P = 0.031*, i.e. a difference in change of ~0.04 units favouring metformin, matching the cited MD 0.04. Caveat: the paper's own prose is internally inconsistent — the RESULTS narrative lists WHR among outcomes where 'on comparing the two groups, the reduction was not significant', and the DISCUSSION summary says neither drug significantly changed WHR — so the 'superiority' framing belongs to the pooled estimate rather than this trial's own conclusion, while the tabulated between-group data support it. (LLM, conf=0.80)
- Not matchedcites [41] Nehra, 2017, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women, Int J Pharm Sci Res
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [42] Nehra, 2017, Comparision of Myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women, Int J Pharm Pharm Sci sourceExperimental — accuracy not yet measured
The Intergroup analysis reports no statistically significant difference in WHR between the myo-inositol and metformin groups at 12 or 24 weeks, and describes a slightly better response with myo-inositol in this trial. The Conclusion calls the drugs equally efficacious. This paper does not report the cited two-trial pooled estimate or its certainty rating. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Meta-analyses · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“women with PCOS are more likely to be affected by insulin resistance irrespective of body mass index (BMI) (4).”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Abstract > Conclusion
What the sources say
- Supportedcites [4] Cassar, 2016, Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies, Hum Reprod source
The Discussion reports that women with PCOS had 27% lower insulin sensitivity than controls, independent of BMI. The Conclusion likewise describes intrinsic insulin resistance independent of BMI, supporting the paraphrase. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“also reduces release of free fatty acids from adipose tissue (8)”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Abstract > Conclusion
What the sources say
- Supportedcites [8] Dinicola, 2021, Inositols: from established knowledge to novel approaches, Int J Mol Sci source
Section 1.1, “Inositol Discovery and Biology,” explicitly states that intracellular myo-inositol reduces free fatty acid release from adipose tissue. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Twenty studies compared MI alone at doses of 1 to 4 g daily either alone or in combination with FA 200 to 400 mcg daily (25-27, 30-34, 41, 42, 44, 46-55) against the comparators of metformin, FA alone, or placebo.”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Intervention
What the sources say
- Not checked — no full text of the sourcecites [25] Akbari Sene, 2019, The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial, Arch Gynecol Obstet source
- Supportedcites [26] Angik, 2015, A comparative study of metabolic and hormonal effects of myoinositol vs metformin in women with polycystic ovary syndrome: a randomised controlled trial, Int J Reprod Contracept Obstet Gynecol source
Angik (2015) is itself one of the trials of the kind the citing sentence enumerates: METHODS describes it as 'randomized controlled Trial with a sample size of 100' PCOS women, and Treatment modality states 'Participants of myoinositol group received myoinositol 1 gm twice daily and, of metformin group received 500 mg metformin tablet twice daily' for 6 months — i.e. myo-inositol alone at 2 g daily (within the claimed 1–4 g/day range) versus metformin, one of the named comparators. The Abstract confirms the same arms and doses. The 'twenty included studies' count is the review's own pooling and is not something this single source carries, but nothing in our copy contradicts the characterisation attached to this citation (no folic acid or placebo arm here simply means it falls under 'MI alone' vs 'metformin'). (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [27] Artini, 2013, Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study, Gynecol Endocrinol source
- Supportedcites [30] Chirania, 2017, A randomised clinical trial comparing myoinositol and metformin in PCOS, Int J Reprod Contracept Obstet Gynecol source
The treatment-group description (Exclusion criteria) identifies this as one of the cited comparisons: patients received myoinositol 1 g/day or metformin 1000 mg/day. The sentence cites multiple studies for the aggregate of twenty; it does not attribute all twenty comparisons or the folic-acid regimens to this trial. (LLM, conf=0.90)
- Not checked yetcites [31] Costantino, 2009, Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial, Eur Rev Med Pharmacol Sci
- Supportedcites [32] Dona, 2012, Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome, Eur J Endocrinol source
The Study protocol (p. 2) identifies this paper as one of the studies described: women with PCOS received myo-inositol alone at 1200 mg/day, within the stated 1–4 g range, or placebo. This citation identifies a constituent study; it does not need to establish the total of twenty studies or every regimen and comparator in the group. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [33] Fruzzetti, 2017, Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS), Gynecol Endocrinol source
- Not checked — no full text of the sourcecites [34] Genazzani, 2008, Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, Gynecol Endocrinol source
- Not matchedcites [41] Nehra, 2017, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women, Int J Pharm Sci Res
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites [42] Nehra, 2017, Comparision of Myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women, Int J Pharm Pharm Sci source
The Materials and Methods and Results sections describe this study as comparing myo-inositol 1 g twice daily (2 g daily), without folic acid, against metformin. It therefore fits one of the study types in the citing sentence; the count of twenty studies is the citing paper’s synthesis, not a claim that Nehra conducted twenty studies. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Three compared the combination of 550 mg MI + 13.8 mg DCI + 200 mcg FA twice daily to FA alone (29, 37, 38).”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Intervention
What the sources say
- Supportedcites [29] Benelli, 2016, A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women, Int J Endocrinol source
Methods §2.1 reports that this trial compared 550 mg MI, 13.8 mg DCI, and 200 μg folic acid twice daily against 200 μg folic acid alone twice daily. The citation identifies this paper as one of the three studies counted by the citing authors; it does not attribute all three studies to this paper. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Supportedcites [37] Khan, 2022, Role of Myo-inositol and D-chiro-inositol in improvement of endocrine and clinical parameters in girls affected by PCOS, Pakistan J Med Health Sci source
The Methodology passage describes this study’s comparison: Group A received 550 mg MI, 13.8 mg DCI, and 200 µg folic acid twice daily; Group B received 200 µg folic acid twice daily. This confirms that the cited paper is one of the studies described, although it does not itself establish the citing paper’s count of three studies. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [38] Le Donne, 2019, Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome, Eur Rev Med Pharmacol Sci doi:10.26355/eurrev_201903_17278
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
90 more claims · 17 with their cited sources checked
Create a free account to see all 195 claims and to verify the 26 references still open.
- Probably not a substantial claim. 67
- It may state two separate claims as one. 50
- The quote only partly states this claim. 4
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Materials and Methods > Search Strategy
“Only randomized controlled trials (RCTs) were included with an a priori defined Participant-Intervention-Comparison-Outcome framework”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results
“Khan 2022 (37)PakistanParallel prospective cohort study”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Narrative Syntheses
“Two studies (n = 84) reported no differences between MI + DCI and MI alone for critical outcomes (HOMA-IR, BMI, FG score) (40, 44).”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results
“550 mg MI + 150 mg DCI twice daily (3.6:1) | 550 mg MI + 13.8 mg DCI twice daily (40:1)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Meta-analyses
“One study comparing MI and metformin reported on depression and quality of life measures (40).”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Outcomes
“One study comparing MI and metformin reported on psychological outcomes (depression and quality of life) (52).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Narrative Syntheses
“Another study (n = 106) (37) compared 500 mg MI in combination with 13.8 mg DCI twice daily for 6 months to FA among a population of teenage girls”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results
“MI + DCI (550 mg of MI, 13.8 mg of DCI, 200 µg FA) twice a day”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| 3 | RCT | Serious risk of biasu | No serious inconsistency | No serious indirectness | Serious imprecisionv | None | 86 | 88 | MD −0.58 [−4.00, 2.33] | Neither (P = .74) | ⨁⨁◯◯LOW | IMPORTANT |”
§ Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines > Results > Meta-analyses
Reported -0.58 · recomputed -0.835
1 more finding
Create a free account to see every finding of this check.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Fifteen trials were conducted in Italy (27, 29, 31-34, 38, 39, 44, 45, 47, 48, 50, 54, 55), 6 in India (26, 28, 30, 36, 41, 42, 51), 2 in Iran (25, 49), 2 in Venezuela (35, 43), and 1 each in Pakistan (37), Turkey (46), Spain (40), Denmark (52), and Bosnia and Herzegovina (53).”
Cited work 10.3109/09513590.2015.1101444 · retraction date not known · this paper published 2024-01-02
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“One study did not clearly define treatment duration (48), and 1 study only provided inositol during IVF stimulation (47).”
Cited work 10.1016/j.fertnstert.2008.01.088 · retracted 2025-02-17 · notice 10.1016/j.fertnstert.2025.01.028 · this paper published 2024-01-02
Citations
Cites
2 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 7×
“One study did not clearly define treatment duration (48), and 1 study only provided inositol during IVF stimulation (47).”
BackgroundMethodInfluentialRetractedPacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111 · cited 4×
“Fifteen trials were conducted in Italy (27, 29, 31-34, 38, 39, 44, 45, 47, 48, 50, 54, 55), 6 in India (26, 28, 30, 36, 41, 42, 51), 2 in Iran (25, 49), 2 in Venezuela (35, 43), and 1 each in Pakistan (37), Turkey (46), Spain (40), Denmark (52), and Bosnia and Herzegovina (53).”
BackgroundMethodInfluentialRetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationTeede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad463 · Cited by 946
Self-citationLim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
Research works printed but not linked: 4
- Teede, 10.26180/24003834.v1.2023 · doi:10.26180/24003834.v1.2023
- Schumemann, 2013, GRADE handbook for Grading of Recommendations Assessment, Development and Evaluation
- Nehra, 2017, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women, Int J Pharm Sci Res, 8, 1664
- Fu, 2015, AHRQ Methods for Effective Health Care. Change Score or Followup Score? An Empirical Evaluation of the Impact of Choice of Mean Difference Estimates
Cited by
International evidence-based recommendations for polycystic ovary syndrome in adolescents
Peña, A. S., Witchel, S. F., Boivin, J., Burgert, T. S., Ee, C., Hoeger, K. M., Lujan, M. E., Mousa, A., Oberfield, S. E., Tay, C. T., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03901-w · Cited by 123
“Inositol preparations cannot currently be recommended in adolescents as no data exist in this population and only biochemical efficacy has been demonstrated in adults with PCOS (Table 4) [1, 45].”
Self-citationPharmacological management of polycystic ovary syndrome
Ee, C., & Tay, C. T. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.030 · Cited by 34
“11 The most commonly used forms of inositol, myo-inositol and D-chiro-inositol, may have limited benefit for some metabolic outcomes in PCOS, including reduced fasting insulin concentration and increased insulin sensitivity.”
BackgroundSelf-citationPalomba, S., Costanzi, F., Caserta, D., & Vitagliano, A. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104381 · Cited by 23
Pandey, C., Maunder, A., Liu, J., Vaddiparthi, V., Costello, M., Khomami, M. B., Mousa, A., & Ee, C. (2024) · Nutrients · doi:10.3390/nu17010057 · Cited by 20
Self-citationBila, J. S., Dotlić, J., Andjić, M., Ivanović, K., Micić, J., Tulić, L., Pupovac, M., Stojnić, J., Vuković, I., & Ivanovic, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165642 · Cited by 25
“Sudden and significant weight loss can worsen pre-existing amenorrhea and PCOS overall, so in such cases, the use of inositol is more advisable [61].”
Metadata
- Authors
- Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C.
- Affiliations
- Massachusetts General Hospital (US)
- University of Wolverhampton (GB)
- Western Sydney University (AU)
- University of Southampton (GB)
- University of Pittsburgh (US)
- Discipline of Paediatrics, The University of Adelaide and Robinson Research Institute , Adelaide 5005 , Australia
- Universidade Federal do Rio Grande do Sul (BR)
- Peking University Third Hospital (CN)
- Monash University (AU)
- Flinders University (AU)
- Corresponding author
- Ee, Carolyn
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-01-02
- Volume
- 109
- Issue
- 6
- Pages
- 1630-1655
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC11099481
- OpenAlex
- W4390508316
- Cited by
- 70
- References
- 64
- Citations by year
- 2026: 35 · 2025: 29 · 2024: 6
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Funders
- Australian National Health and Medical Research Council
- NHMRC
- Centre for Research Excellence in Women’s Health in Reproductive Life
- CRE WHIRL
- NHMRC CRE WHIRL
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, insulin sensitization, metformin, ovulation, hirsutism, body mass index, waist-to-hip ratio, gastrointestinal adverse effects, shared decision-making
- MeSH terms
- Female, Humans, Inositol, Insulin Resistance, Polycystic Ovary Syndrome, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. https://app.cochat.ai/papers/10.1210/clinem/dgad762
- The paper
- Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad762
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.